The Manufacturers Life Insurance Company Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

The Manufacturers Life Insurance Company decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 338,044 shares of the biopharmaceutical company's stock after selling 2,522 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.31% of Regeneron Pharmaceuticals worth $355,365,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in REGN. Quent Capital LLC increased its holdings in shares of Regeneron Pharmaceuticals by 5.1% in the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company's stock worth $375,000 after buying an additional 19 shares during the period. CreativeOne Wealth LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $200,000. Gamco Investors INC. ET AL purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $230,000. Kennedy Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $5,210,000. Finally, Tidal Investments LLC increased its holdings in shares of Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company's stock worth $4,774,000 after buying an additional 711 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on REGN. Barclays decreased their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Evercore ISI cut their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Finally, Truist Financial cut their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of REGN traded up $3.52 during mid-day trading on Tuesday, reaching $753.03. The company had a trading volume of 779,729 shares, compared to its average volume of 543,241. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a 50-day moving average price of $929.13 and a 200 day moving average price of $1,024.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The company has a market capitalization of $82.75 billion, a price-to-earnings ratio of 18.63, a price-to-earnings-growth ratio of 2.84 and a beta of 0.15.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.48% of the company's stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.